JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia

International Journal of Hematology-Oncology and Stem Cell Research

Volumn 3, Issue 4, 2009, Pages 43-45

  Nadali, F ^a   Ferdowsi, Sh ^c   Karimzadeh, P ^c   Chahardouli, B ^b   Einollahi, N ^c   Mousavi, S A ^b   Bahar, B ^b   Dargahi, H ^c   Alimoghaddam, K ^b   Ghavamzadeh, A ^b   Ghaffari, S H ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ARMS PCR; ASO PCR; BCR ABL translocation; JAK2V617F mutation

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; JANUS KINASE 2;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; MALE; POINT MUTATION; PROTEIN EXPRESSION;

EID: 79952416641     PISSN: 17351243     EISSN: 20082207     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2-V617F Mutation in CML. Lancet Oncol, 2007; 8: 864-6.
2. Mirza I, Frantz C, Clarke G, et al. Transformation of Polycythemia Vera to Chronic Myelogenous Leukemia. Arch Pathol Lab Med, 2007; 131: 1719-24.
3. Hussein K, Bock O, Seegers A, et al. Myelofibrosis Evolving During Imatinib Treatment of a Chronic Myeloproliferative Disease with Coexisting BCR-ABL Translocation and JAK2V617F mutation. Blood 2007; 109: 4106-7.
4. Bornhauser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2 (V617F) Mutation and BCR-ABL Translocation within Committed Myeloid Progenitors in Myelofibrosis. Leukemia 2007; 21: 1824-6.
5. Curtin NJ, Campbell PJ, Green AR. The Philadelphia Translocation and Pre-existing Myeloproliferative Disorders. Br J Haematol, 2005; 128: 734-6.
6. Fialkow PJ, Martin PJ, Najfeld V, et al. Evidence for a Multistep Pathogenesis of Chronic Myelogenous Leukemia. Blood, 1981; 58: 158- 63.
7. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F Mutation of JAK2 is a Late Genetic Event in a Subset of Patients with Myeloproliferative Disorders. Blood, 2006; 108: 1377- 80.
8. Haq, AU. Transformation of Polycythemia Vera to Phpositive Chronic Myelogenous Leukemia. Am J Hematol, 1990; 35: 110- 13.
9. Jones AV, Kreil S, Zoi K, et al: Widespread Occurrence of the JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. Blood, 2005; 106: 2162-2168.
10. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 Mutation 1849G>T is Rare in Acute Leukemias but Can be Found in CMML, Philadelphia Chromosome-negative CML, and Megakaryocytic Leukemia. Blood 2005;106: 3370-3.
11. Jallades L, Hayette S, Tigaud I, et al. Emergence of Therapy-unrelated CML on a Background of BCR-ABLnegative JAK2 V617F-positive Chronic Idiopathicmyelofibrosis. Leuk Res, 2008; 32: 1608-10.
12. Bornhäuser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2 (V617F) Mutation and BCR-ABL Translocation within Committed Myeloid Progenitors in Myelofibrosis. Leukemia, 2007; 21: 1824-6.
13. Mello Conchon M, Costa JL, Novaes M, et al. Simultaneous detection of JAK2 V617F Mutation and Bcr- Abl Translocation in a Patient with Chronic Myelogenous Leukemia. Int J Hematol, 2008; 88: 243-245.
14. Kr̈amer A, Reiter A, Kruth J, et al. JAK2-V617F Mutation in a Patient with Philadelphia-chromosomepositive Chronic Myeloid Leukaemia. Lancet Oncol, 2007; 8: 658-60.
15. Inami M, Inokuchi K, Okabe M, et al. Polycythemia Associated with the JAK2V617F Mutation Emerged During Treatment of Chronic Myelogenous Leukemia. Leukemia, 2007; 21: 1103-4.
16. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 Mutation is Uncommon in Cancers and in Myeloid Malignancies other than the Classic Myeloproliferative Disorders. Blood, 2005; 106: 2920-1.